EA200702493A1 - Соединения и способы лечения или предотвращения флавивирусных инфекций - Google Patents

Соединения и способы лечения или предотвращения флавивирусных инфекций

Info

Publication number
EA200702493A1
EA200702493A1 EA200702493A EA200702493A EA200702493A1 EA 200702493 A1 EA200702493 A1 EA 200702493A1 EA 200702493 A EA200702493 A EA 200702493A EA 200702493 A EA200702493 A EA 200702493A EA 200702493 A1 EA200702493 A1 EA 200702493A1
Authority
EA
Eurasian Patent Office
Prior art keywords
prevention
connections
treatment
methods
flavivirus infections
Prior art date
Application number
EA200702493A
Other languages
English (en)
Other versions
EA016071B1 (ru
Inventor
Реал Дени
Карл Пуассон
Санджой Кумар Дас
Ирина Моторина
Рабиндра Редж
Константин Г. Яннопулос
Лаваль Чань Чунь Кун
Original Assignee
Вирокем Фарма Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Вирокем Фарма Инк. filed Critical Вирокем Фарма Инк.
Publication of EA200702493A1 publication Critical patent/EA200702493A1/ru
Publication of EA016071B1 publication Critical patent/EA016071B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40—Thiophene-2-carboxylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Соединения, представленные формулой Iили их фармацевтически приемлемые соли и сольваты, где R, X, Y, Yи Z являются такими, как определено в описании, которые могут использоваться для лечения инфекций вируса Flaviviridae.
EA200702493A 2005-05-13 2006-05-15 Соединения и способы лечения или предотвращения флавивирусных инфекций EA016071B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68048205P 2005-05-13 2005-05-13
PCT/CA2006/000786 WO2006119646A1 (en) 2005-05-13 2006-05-15 Compounds and methods for the treatment or prevention of flavivirus infections

Publications (2)

Publication Number Publication Date
EA200702493A1 true EA200702493A1 (ru) 2008-04-28
EA016071B1 EA016071B1 (ru) 2012-01-30

Family

ID=37396165

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200702493A EA016071B1 (ru) 2005-05-13 2006-05-15 Соединения и способы лечения или предотвращения флавивирусных инфекций

Country Status (17)

Country Link
US (3) US7569600B2 (ru)
EP (3) EP2546246A3 (ru)
JP (1) JP5030947B2 (ru)
KR (1) KR20080016597A (ru)
CN (2) CN101218224B (ru)
AP (1) AP2007004245A0 (ru)
AU (1) AU2006246227B2 (ru)
BR (1) BRPI0610283A2 (ru)
CA (1) CA2607359C (ru)
EA (1) EA016071B1 (ru)
ES (1) ES2415742T3 (ru)
HK (1) HK1112910A1 (ru)
MX (1) MX2007014117A (ru)
NZ (1) NZ563909A (ru)
SG (1) SG161315A1 (ru)
WO (1) WO2006119646A1 (ru)
ZA (1) ZA200709727B (ru)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1401825E (pt) * 2001-06-11 2009-10-23 Virochem Pharma Inc Compostos e métodos para o tratamento ou para a prevenção de infecções com flavivírus
US8329924B2 (en) * 2001-06-11 2012-12-11 Vertex Pharmaceuticals (Canada) Incorporated Compounds and methods for the treatment or prevention of Flavivirus infections
JP5030947B2 (ja) 2005-05-13 2012-09-19 ヴァイロケム・ファーマ・インコーポレーテッド フラビウイルス感染の治療及び予防のための化合物及び方法
KR20090086081A (ko) 2006-11-15 2009-08-10 바이로켐 파마 인코포레이티드 플라비바이러스 감염의 치료 또는 예방용 티오펜 유사체
JP2010521457A (ja) * 2007-03-12 2010-06-24 メルク・シャープ・エンド・ドーム・コーポレイション 単環式アニリドスピロラクタムｃｇｒｐ受容体アンタゴニスト
SI2308514T1 (sl) 2007-03-23 2013-09-30 To-Bbb Holding B.V. Konjugati za prenos zdravila preko krvno-moĹľganske pregrade
ATE548044T1 (de) 2007-05-04 2012-03-15 Vertex Pharma Kombinationstherapie zur behandlung von hiv- infektionen
JP2010528051A (ja) 2007-05-23 2010-08-19 シガ・テクノロジーズ・インコーポレーテッド デング感染症の治療または予防のための抗ウイルス薬
GB0712393D0 (en) * 2007-06-26 2007-08-01 Smithkline Beecham Corp Compounds
AU2008338273B2 (en) 2007-12-19 2014-10-02 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US20110212986A1 (en) * 2008-08-21 2011-09-01 Health Research, Inc. Anti-flavivirus therapeutic
MX2011007195A (es) 2009-01-07 2013-07-12 Scynexis Inc Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
JP5327744B2 (ja) * 2009-03-13 2013-10-30 国立大学法人 鹿児島大学 ジフェニルメタン誘導体を有効成分とする抗ウイルス剤
UY32793A (es) * 2009-07-21 2011-01-31 Gilead Sciences Inc Compuestos inhibidores de los virus flaviviridae, composición farmacéutica que los contiene y sus usos
KR20120081123A (ko) 2009-09-09 2012-07-18 길리애드 사이언시즈, 인코포레이티드 플라비비리대 바이러스의 억제제
US8618307B2 (en) 2009-09-16 2013-12-31 Calcimedica, Inc. Compounds that modulate intracellular calcium
MX2012006026A (es) 2009-11-25 2012-08-15 Vertex Pharma Derivados de acido 5-alquinil-tiofen-2-carboxilico y usos para tratamiento o prevencion de infecciones por flavivirus.
JP5777223B2 (ja) 2010-01-15 2015-09-09 ギリアード サイエンシーズ， インコーポレイテッド フラビウイルス科ウイルスのインヒビター
AP3576A (en) * 2010-01-15 2016-02-08 Gilead Sciences Inc Inhibitors of flaviviridae viruses
EP2585447A2 (en) 2010-06-28 2013-05-01 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
WO2012006060A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
MX2013001869A (es) 2010-08-17 2013-06-28 Vertex Pharma Compuestos y metodos para el tratamiento o prevencion de infecciones virales por flaviviridae.
US8771665B2 (en) 2010-12-17 2014-07-08 Cocrystal Discovery, Inc. Inhibitors of hepatitis C virus polymerase
US20130203706A1 (en) * 2011-06-28 2013-08-08 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
WO2013010112A1 (en) * 2011-07-13 2013-01-17 Gilead Sciences, Inc. Thiophen-2-carboxylic acid derivatives useful as inhibitors of flaviviridae viruses
CN103059042B (zh) * 2011-10-18 2015-10-07 银杏树药业(苏州)有限公司 噻吩类衍生物及其在药学中的用途
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
GB2506086A (en) 2011-10-21 2014-03-19 Abbvie Inc Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CA2811250C (en) 2011-10-21 2015-08-11 Abbvie Inc. Methods for treating hcv
CN103087052A (zh) * 2011-10-31 2013-05-08 上海壹志医药科技有限公司 噻吩衍生物及其药物用途
WO2014055142A1 (en) 2012-06-20 2014-04-10 Cocrystal Discovery, Inc. Inhibitors of hepatitis c virus polymerase
US8841340B2 (en) 2012-08-17 2014-09-23 Gilead Sciences, Inc. Solid forms of an antiviral compound
US8759544B2 (en) 2012-08-17 2014-06-24 Gilead Sciences, Inc. Synthesis of an antiviral compound
US8927741B2 (en) 2012-08-17 2015-01-06 Gilead Sciences, Inc. Synthesis of an antiviral compound
TWI731854B (zh) 2015-03-23 2021-07-01 美商共結晶製藥公司 Ｃ型肝炎病毒聚合酶之抑制劑
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
CN106467477A (zh) * 2016-08-26 2017-03-01 天津雅奥科技发展有限公司 一种合成化合物（1‑环丙基‑1‑氰基‑4‑环己酮）的新方法
CN112203652A (zh) 2018-05-09 2021-01-08 共晶制药公司 用于治疗hcv的组合疗法
WO2019244047A1 (en) 2018-06-19 2019-12-26 Novartis Ag N-substituted tetrahydrothienopyridine derivatives and uses thereof
CN110592172B (zh) * 2019-10-29 2021-05-28 华中农业大学 利用CRISPR/Cas9敲除文库技术筛选JEV抗性基因的方法与靶点
CN111518015A (zh) * 2020-05-20 2020-08-11 上海合全药物研发有限公司 一种叔丁基-8-氧亚基-2-氮杂螺[4.5]癸烷-2-甲酸基酯的制备方法
CN113861176B (zh) * 2021-09-28 2023-11-03 北京凯因格领生物技术有限公司 一种黄病毒抑制剂
EP4282862A1 (en) * 2022-05-25 2023-11-29 Irbm S.P.A. Flavivirus inhibitors

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3076817A (en) 1963-02-05 New j-amino-thiophene-z
DE1055007B (de) 1957-08-29 1959-04-16 Dr Hans Fiesselmann Verfahren zur Herstellung von 3-Aminothiophen-2-carbonsaeureestern und den entsprechenden freien Carbonsaeuren
US3470151A (en) 1966-05-17 1969-09-30 Beecham Group Ltd Furyl- and thienyl-penicillins and salts thereof
AU518216B2 (en) 1977-09-06 1981-09-17 Hafslund Nycomed Pharma Aktiengesellschaft Thienothiazine derivatives
GB8627698D0 (en) 1986-11-20 1986-12-17 Boots Co Plc Therapeutic agents
US4962101A (en) 1989-08-21 1990-10-09 Merck & Co., Inc. 2-(Heterocyclylalkyl)phenyl carbapenem antibacterial agents
JPH0748360A (ja) 1993-05-31 1995-02-21 Yoshitomi Pharmaceut Ind Ltd ビフェニルテトラゾール誘導体
HU227742B1 (en) 1996-10-18 2012-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
JP4000608B2 (ja) 1996-11-07 2007-10-31 トヨタ自動車株式会社 水素製造充填装置および電気自動車
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
AU6959898A (en) 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
TR200101905T2 (tr) 1997-04-28 2002-06-21 Texas Biotechnology Corporation Endotelin ile ilgili hastalıkların tedavisinde kullanılan sülfanoamidler.
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
DE69826695T2 (de) 1997-05-23 2006-02-02 Bayer Pharmaceuticals Corp., West Haven Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
EP0986382B1 (en) 1997-05-23 2008-06-25 Bayer Pharmaceuticals Corporation Raf kinase inhibitors
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
DE69829381T2 (de) 1997-08-11 2006-04-13 Boehringer Ingelheim (Canada) Ltd., Laval Hepatitis c inhibitor peptide
ATE283865T1 (de) 1997-08-11 2004-12-15 Boehringer Ingelheim Ca Ltd Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
DK0957099T3 (da) 1998-04-15 2003-03-17 Pfizer Prod Inc Heterocykliske carboxamider
EP0960882A1 (en) 1998-05-19 1999-12-01 Hoechst Marion Roussel Deutschland GmbH Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists
US6858223B2 (en) 1998-06-23 2005-02-22 Altana Pharma Ag Compositions comprising phenylaminothiophenacetic acid derivatives for the treatment of acute or adult respiratory distress syndrome (ARDS) and infant respiratory distress syndrome (IRDS)
AU4385399A (en) 1998-06-29 2000-01-17 Biochem Pharma Inc. Thiophene and furan 2,5-dicarboxamides useful in the treatment of cancer
JP2003525200A (ja) 1998-07-27 2003-08-26 イスティトゥト ディ リチェルケ ディ ビオロジア モレコラーレ ピー．アンジェレッティ ソチエタ ペル アツィオニ ポリメラーゼ阻害剤としてのジケト酸誘導体
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
NZ509252A (en) 1998-08-20 2004-05-28 Agouron Pharma Non-peptide GnRH agents for treating GnRH associated diseases with pyrazole carboxamidine related structures
DE19903398A1 (de) 1999-01-29 2000-08-10 Hassan Jomaa Verwendung von Thiadiazolderivaten zur prophylaktischen und therapeutischen Behandlung von Infektionen
ATE278674T1 (de) 1999-03-12 2004-10-15 Boehringer Ingelheim Pharma Heterocyklischer harnstoff und verwandte verbindungen als entzündungshemmende mittel
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
JP2001010957A (ja) 1999-04-28 2001-01-16 Sankyo Co Ltd 肝障害の予防または抑制剤
DE19920247A1 (de) 1999-05-03 2000-11-16 Hassan Jomaa Arzneimittel mit einem Gehalt an Verbindungen mit einem Stickstoff-Sauerstoff-Heterocyclus als Wirkstoff und ihre Verwendung
HN2000000051A (es) 1999-05-19 2001-02-02 Pfizer Prod Inc Derivados heterociclicos utiles como agentes anticancerosos
AU7446600A (en) * 1999-10-01 2001-05-10 Japan Energy Corporation Novel diarylamide derivatives and use thereof as medicines
NZ518697A (en) 1999-11-29 2004-02-27 Novartis Ag Pesticidal N-heteroaryl alpha-alkoximino-carboxamides
CN1623984A (zh) 1999-12-27 2005-06-08 日本烟草产业株式会社 稠环化合物及其药物用途
DE10002424A1 (de) 2000-01-20 2001-07-26 Siemens Ag Di(het)arylaminothiophen-Derivate
WO2001085172A1 (en) 2000-05-10 2001-11-15 Smithkline Beecham Corporation Novel anti-infectives
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US6414013B1 (en) 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
WO2002028353A2 (en) 2000-10-05 2002-04-11 Smithkline Beecham Corporation Phosphate transport inhibitors
MXPA03004016A (es) 2000-11-08 2004-02-12 Syngenta Participations Ag Pirrolcarboxamidas y pirrolcarbotioamidas y sus usos agroquimicos.
DE60119968T2 (de) 2000-11-20 2007-01-18 Bristol-Myers Squibb Co. Hepatitis c tripeptid inhibitoren
US6892279B2 (en) 2000-11-30 2005-05-10 Mosaid Technologies Incorporated Method and apparatus for accelerating retrieval of data from a memory system with cache by reducing latency
DE10061876A1 (de) 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
EP2399588B1 (en) 2001-01-22 2020-04-29 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
AU2002252183A1 (en) 2001-03-06 2002-09-19 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
US6734207B2 (en) 2001-04-20 2004-05-11 Parker Hughes Institute Cytotoxic compounds
EP1256628A3 (en) 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
US6713638B2 (en) 2001-05-18 2004-03-30 Joel M. Linden 2-amino-3-aroyl-4,5 alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptors
AR036081A1 (es) 2001-06-07 2004-08-11 Smithkline Beecham Corp Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
JP2005500287A (ja) 2001-06-11 2005-01-06 シャイアー バイオケム インコーポレイテッド Ｆｌａｖｉｖｉｒｕｓ感染の処置または予防のための化合物および方法
PT1401825E (pt) * 2001-06-11 2009-10-23 Virochem Pharma Inc Compostos e métodos para o tratamento ou para a prevenção de infecções com flavivírus
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
SE0102617D0 (sv) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
EP1429759A4 (en) 2001-09-26 2004-12-15 Bristol Myers Squibb Co COMPOUNDS FOR TREATING HEPATITIS C VIRUS
JP2005506334A (ja) 2001-10-04 2005-03-03 スミスクライン・ビーチャム・コーポレイション ＮＦ−κＢ阻害剤
ATE539744T1 (de) 2001-10-24 2012-01-15 Vertex Pharma Hemmer von serin-protease, insbesondere von hepatitis-c-virus-ns3-ns4a-protease, mit einem kondensierten ringsystem
TWI281916B (en) 2001-10-25 2007-06-01 Lilly Co Eli Antitumor compounds and methods
AU2002352443A1 (en) 2001-12-21 2003-07-15 Consejo Superior De Investigaciones Cientificas Compounds and their therapeutic use related to the phosphorylating activity of the enzyme gsk-3
US6835745B2 (en) 2002-01-15 2004-12-28 Wyeth Phenyl substituted thiophenes as estrogenic agents
DE10203122A1 (de) 2002-01-25 2003-07-31 Gruenenthal Gmbh Verfahren zur Herstellung von substituierten Acrylsäureestern bzw. deren Einsatz zur Herstellung von substituierten gamma-Aminosäuren
PL373399A1 (en) 2002-04-11 2005-08-22 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
AU2003232071A1 (en) 2002-05-06 2003-11-17 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis c virus infection
US7109354B2 (en) 2002-05-28 2006-09-19 3-Dimensional Pharmaceuticals, Inc. Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
US7179836B2 (en) 2002-09-20 2007-02-20 Smithkline Beecham Corporation Chemical compounds
ES2345438T3 (es) 2002-12-10 2010-09-23 Virochem Pharma Inc. Compuestos y metodos para el tratamiento o prevencion de infecciones por flavivirus.
EP1569929B9 (en) * 2002-12-10 2011-09-14 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of flavivirus infections
US20040192707A1 (en) 2002-12-10 2004-09-30 Laval Chan Chun Kong Compounds and methods for the treatment or prevention of Flavivirus infections
US7098241B2 (en) 2002-12-16 2006-08-29 Hoffmann-La Roche Inc. Thiophene hydroxamic acid derivatives
WO2004092161A1 (en) 2003-04-11 2004-10-28 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
ES2381548T3 (es) 2003-04-11 2012-05-29 Vertex Pharmaceuticals Incorporated Inhibidores de serina proteasas, particularmente de la proteasa VHC NS3-NS4A
US20050113566A1 (en) 2003-04-25 2005-05-26 Player Mark R. Inhibitors of C-FMS kinase
CA2523808A1 (en) 2003-05-16 2004-12-23 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
US7345046B2 (en) 2003-05-30 2008-03-18 Chiron Corporation Heteroaryl-fused pyrimidinyl compounds as anticancer agents
CN101724022A (zh) 2003-07-18 2010-06-09 沃泰克斯药物股份有限公司 丝氨酸蛋白酶抑制剂、特别是hcv ns3-ns4a蛋白酶抑制剂
UY28500A1 (es) 2003-09-05 2005-04-29 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc.
US20050119189A1 (en) 2003-09-18 2005-06-02 Cottrell Kevin M. Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
GB0324653D0 (en) 2003-10-22 2003-11-26 Syngenta Participations Ag Fungicides
DE10359791A1 (de) 2003-12-19 2005-07-21 Bayer Healthcare Ag Substituierte Thiophene
JP2008505849A (ja) 2004-02-04 2008-02-28 バーテックス　ファーマシューティカルズ　インコーポレイテッド セリンプロテアーゼ、特に、ｈｃｖ、ｎｓ３−ｎｓ４ａプロテアーゼの阻害剤
WO2006093518A2 (en) 2004-06-25 2006-09-08 Apath, Llc Thienyl compounds for treating virus-related conditions
EP1771169A1 (en) 2004-07-14 2007-04-11 PTC Therapeutics, Inc. Methods for treating hepatitis c
FR2873692B1 (fr) 2004-07-29 2006-12-01 Univ Claude Bernard Lyon COMPOSITIONS CONTENANT, EN ASSOCIATION AVEC UN AGENT ANTIMICROBIEN, UN COMPOSE THIOPHENIQUE OU BENZOTHIOPHENIQUE DE FORMULE(I)PRESENTANT UNE ACTIVITE INHIBITRICE DE POMPE NorA
CA2583472A1 (en) 2004-10-01 2006-04-13 Chao Lin Hcv ns3-ns4a protease inhibition
DE102004061746A1 (de) 2004-12-22 2006-07-06 Bayer Healthcare Ag Alkinyl-substituierte Thiophene
DE102005028077A1 (de) 2004-12-22 2006-07-13 Aicuris Gmbh & Co. Kg Alkinyl-substituierte Thiophene
JP5030947B2 (ja) * 2005-05-13 2012-09-19 ヴァイロケム・ファーマ・インコーポレーテッド フラビウイルス感染の治療及び予防のための化合物及び方法
JP2006334109A (ja) 2005-06-01 2006-12-14 Matsushita Electric Works Ltd ヘアセット装置
KR20090086081A (ko) 2006-11-15 2009-08-10 바이로켐 파마 인코포레이티드 플라비바이러스 감염의 치료 또는 예방용 티오펜 유사체

Also Published As

Publication number Publication date
CN101218224A (zh) 2008-07-09
HK1112910A1 (en) 2008-09-19
US20060276533A1 (en) 2006-12-07
CN102718744A (zh) 2012-10-10
CA2607359C (en) 2011-08-09
AU2006246227B2 (en) 2011-04-28
KR20080016597A (ko) 2008-02-21
EP2546246A2 (en) 2013-01-16
SG161315A1 (en) 2010-05-27
NZ563909A (en) 2011-10-28
US20100093775A1 (en) 2010-04-15
US8674118B2 (en) 2014-03-18
EA016071B1 (ru) 2012-01-30
AU2006246227A1 (en) 2006-11-16
JP2008540463A (ja) 2008-11-20
CA2607359A1 (en) 2006-11-16
US7569600B2 (en) 2009-08-04
ES2415742T3 (es) 2013-07-26
EP1879879A4 (en) 2010-03-10
EP2543664A1 (en) 2013-01-09
EP2546246A3 (en) 2013-04-24
MX2007014117A (es) 2008-02-05
ZA200709727B (en) 2008-11-26
WO2006119646A1 (en) 2006-11-16
JP5030947B2 (ja) 2012-09-19
US20120164103A1 (en) 2012-06-28
AP2007004245A0 (en) 2007-12-31
CN101218224B (zh) 2013-05-08
EP1879879B1 (en) 2013-03-27
US8158675B2 (en) 2012-04-17
BRPI0610283A2 (pt) 2010-10-19
EP1879879A1 (en) 2008-01-23

Similar Documents

Publication Publication Date Title
EA200702493A1 (ru) Соединения и способы лечения или предотвращения флавивирусных инфекций
EA200901241A1 (ru) Соединения для лечения гепатита с
TW200639169A (en) Bicyclic heteroaryl derivatives for treating viruses
EA201101492A1 (ru) Аналоги тиофена для лечения или предупреждения флавивирусных инфекций
EA201000201A1 (ru) Азотсодержащие бициклические химические вещества для лечения вирусных инфекций
NO20062146L (no) Nukleosidforbindelser for behandling av virusinfeksjoner
EA201100390A1 (ru) Соединения для лечения гепатита с
EA200800371A1 (ru) Ингибиторы ns3 протеазы вгс
EA201290053A1 (ru) Ингибиторы вирусов flaviviridae
NO20092053L (no) HCV NS3-proteaseinhibitorer
ATE469155T1 (de) Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b- hemmer
ATE483712T1 (de) Hcv-ns5b-inhibitoren
BRPI0612124A2 (pt) derivados de heteroarila para o tratamento de viroses
HRP20070435A9 (en) Tricyclic-nucleoside compounds for treating viral infections
EA201390822A1 (ru) Макроциклические ингибиторы вирусов flaviviridae
EA201001273A1 (ru) Ингибиторы вируса гепатита с
EA201200669A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
EA200800760A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
TW200719898A (en) 6-membered aryl and heteroaryl derivatives for treating viruses
IN2012DN01855A (ru)
EA201000277A1 (ru) Соединения для лечения гепатита с
DK2209789T3 (da) Cyclopropyl-kondenserede indolobenzazepin HCV NS5B-hæmmere
MX2012006026A (es) Derivados de acido 5-alquinil-tiofen-2-carboxilico y usos para tratamiento o prevencion de infecciones por flavivirus.
ATE551343T1 (de) Tetracyclische verbindungen zur behandlung von hepatitis c
EA201000051A1 (ru) Противовирусные соединения, композиции и способы использования

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU